{
    "clinical_study": {
        "@rank": "78916", 
        "arm_group": {
            "arm_group_label": "CAZ-AVI", 
            "arm_group_type": "Experimental", 
            "description": "This arm will include 4 cohorts. Patients will be stratified by age."
        }, 
        "brief_summary": {
            "textblock": "To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in\n      children from 3 months of age to <18 years."
        }, 
        "brief_title": "Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Infections", 
        "condition_browse": {
            "mesh_term": "Sepsis"
        }, 
        "detailed_description": {
            "textblock": "This is a phase I, open-label, single-dose study. The study aims to characterize the\n      pharmacokinetics of CAZ-AVI and assess its safety and tolerability following a single IV\n      dose given to hospitalized pediatric patients receiving systemic antibiotic therapy for\n      suspected or confirmed infection. This study will include 4 cohorts, each consisting of at\n      least 8 evaluable pediatric patients, aged \u22653 months to <18 years, who are hospitalized with\n      infections."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent will be obtained from parent(s) or other legally acceptable\n             representative(s), and informed assent from patient (if age appropriate) will be\n             obtained\n\n          2. Male or female children ages \u22653 months to <18 years.\n\n          3. Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected\n             or confirmed infection, and expected to require hospitalization until after the end\n             of treatment (EOT) evaluations are completed.\n\n          4. If female and has reached menarche, or has reached Tanner stage 3 breast development\n             (even if not having reached menarche), the patient is practicing appropriate birth\n             control or is sexually abstinent.\n\n          5. Likely to survive the current illness or hospitalization.\n\n          6. Sufficient intravascular access (peripheral or central) to receive study drug.\n\n        Exclusion Criteria:\n\n          1. History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin,\n             other \u03b2-lactam antibiotics.\n\n          2. If female, currently pregnant or breast feeding or has a positive serum \u03b2-human\n             chorionic gonadotropin (\u03b2-hCG) pregnancy test.\n\n          3. Receipt of a blood or blood component (e.g., red blood cells, fresh frozen plasma,\n             platelets) transfusion during the 24-hour period before enrolment.\n\n          4. BMI outside the range (below the 5th percentile or above the 85th percentile) for\n             height, age, and weight except for children <2 years of age.\n\n          5. Babies born prior to 37 weeks gestation (cohort 4 only)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893346", 
            "org_study_id": "D4280C00014"
        }, 
        "intervention": {
            "arm_group_label": "CAZ-AVI", 
            "description": "Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.", 
            "intervention_name": "CAZ-AVI", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ceftazidime"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Ceftazidime, Avibactam, Anti-Infectives", 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "AstraZeneca Clinical Study Information", 
            "phone": "800-236-9933"
        }, 
        "overall_contact_backup": {
            "email": "Arvil.Stephens@ppdi.com", 
            "last_name": "Arvil Stephens", 
            "phone": "1-910-558-7573"
        }, 
        "overall_official": {
            "affiliation": "AstraZeneca", 
            "last_name": "Paul Newell, MBBS, MRCP", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured PK parameters will include ceftazidime and avibactam collection times and plasma concentration data by patient and cohort. In addition, non-compartmental PK parameters will be calculated for Cohort 1.", 
            "measure": "Plasma pharmacokinetics parameters of ceftazidime and avibactam following single dose of CAZ-AVI in pediatric patients.", 
            "safety_issue": "No", 
            "time_frame": "From end of infusion to 6-22 hours post end of infusion, depending on cohort."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Assessment of the safety and tolerability of a single IV dose of CAZ-AVI given to hospitalized patients via Adverse Events, Vital Signs, Physical Examination, Laboratory Parameters and ECGs.", 
            "safety_issue": "Yes", 
            "time_frame": "From consent to 48 hours post-dose"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Cerexa, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}